Emd Serono Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EMD SERONO, and when can generic versions of EMD SERONO drugs launch?
EMD SERONO has nine approved drugs.
There are twelve US patents protecting EMD SERONO drugs.
There are one hundred and seventy-three patent family members on EMD SERONO drugs in forty countries and seventy-six supplementary protection certificates in sixteen countries.
Summary for Emd Serono
| International Patents: | 173 |
| US Patents: | 12 |
| Tradenames: | 8 |
| Ingredients: | 7 |
| NDAs: | 9 |
Drugs and US Patents for Emd Serono
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emd Serono Inc | TEPMETKO | tepotinib hydrochloride | TABLET;ORAL | 214096-001 | Feb 3, 2021 | RX | Yes | Yes | 9,403,799 | See Plans and Pricing | See Plans and Pricing | ||||
| Emd Serono Inc | TEPMETKO | tepotinib hydrochloride | TABLET;ORAL | 214096-001 | Feb 3, 2021 | RX | Yes | Yes | 8,927,540 | See Plans and Pricing | See Plans and Pricing | ||||
| Emd Serono Inc | GEREF | sermorelin acetate | INJECTABLE;INJECTION | 020443-002 | Sep 26, 1997 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Emd Serono
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Emd Serono | NOVANTRONE | mitoxantrone hydrochloride | INJECTABLE;INJECTION | 019297-003 | Dec 23, 1987 | 4,820,738 | See Plans and Pricing |
| Emd Serono Inc | CETROTIDE | cetrorelix | INJECTABLE;INJECTION | 021197-002 | Aug 11, 2000 | 7,605,121 | See Plans and Pricing |
| Emd Serono Inc | CETROTIDE | cetrorelix | INJECTABLE;INJECTION | 021197-001 | Aug 11, 2000 | 7,605,121 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Emd Serono Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Eurasian Patent Organization | 009714 | See Plans and Pricing |
| South Korea | 20060011943 | See Plans and Pricing |
| Singapore | 160391 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Emd Serono Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1608344 | C 2018 009 | Romania | See Plans and Pricing | PRODUCT NAME: CLADRIBINA; NATIONAL AUTHORISATION NUMBER: EU/1/17/1212; DATE OF NATIONAL AUTHORISATION: 20170822; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1212; DATE OF FIRST AUTHORISATION IN EEA: 20170822 |
| 1827461 | 18C1008 | France | See Plans and Pricing | PRODUCT NAME: CLADRIBINE; REGISTRATION NO/DATE: EU/1/17/1212 20170824 |
| 1506211 | 132014902277722 | Italy | See Plans and Pricing | PRODUCT NAME: UNA COMBINAZIONE DI DAPAGLIFLOZIN O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE E METFORMINA O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE COME PROTETTI DAL BREVETTO DI BASE EP1506211(XIGDUO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/900, 20140116 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
